Investor Presentaiton slide image

Investor Presentaiton

Major R&D Milestones (Alpha) DS-7300 Project Quizartinib Valemetostat (DS-3201) DS-9606 • . • Target Indication [phase, study name] • ES-SCLC, 2L [P2, JP/US/EU/Asia] AML, 1L [P3, JP/US/EU/Asia] ATL/L [Registrational P2, JP] Solid tumors [P1, US/EU] • . H1 FY2022 Study started Filing anticipated (JP/US/EU) • Approval anticipated (JP) ⚫ Study started DS-2325 • Netherton syndrome [P1, US] DS-5670 • COVID-19 mRNA vaccine, booster [P1/2/3, JP] . • Study started H2 12 • TLR anticipated As of Jul 2022 Daiichi-Sankyo • Filing anticipated (JP) Bold: update from FY2021 Q4 AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, ES-SCLC: extensive stage-small cell lung cancer, TLR: top line results The timeline indicated is based on the current forecast and subject to change. FY2023 • Approval anticipated (JP/US/EU) 40
View entire presentation